Please provide your email address to receive an email when new articles are posted on . The average health care cost per patient in the indwelling pleural catheter (IPC) group was $40,179 vs. $46,640 ...

Introduction Malignant pleural effusion (MPE) affects up to 15% of patients with cancer, and its incidence and prevalence are increasing. 1 - 4 Most cases are symptomatic; the most common symptoms are ...

DelveInsight's“ Malignant Pleural Effusion Pipeline Insight” report provides comprehensive global coverage of pipeline therapies for Malignant Pleural Effusion across various stages of clinical ...

A retrospective cohort of adults hospitalized for MPE from 2009 to 2011 was analyzed using an administrative database. The primary outcome was all-cause 30-day readmission rate. Hierarchic ...

Leading Malignant Pleural Effusion companies in the market include - RS Oncology, Genelux Corporation, Candel Therapeutics, and others. The Malignant Pleural Effusion Market is projected to experience ...

MINNEAPOLIS--(BUSINESS WIRE)--The Centers for Medicare and Medicaid Services (CMS) has issued a new Healthcare Common Procedure Coding System (HCPCS) code and New Technology Ambulatory Payment ...

Researchers at Wake Forest School of Medicine have discovered that a nanoparticle therapeutic enhances cancer immunotherapy and is a possible new approach in treating malignant pleural effusion (MPE).

Cryopreserved cell-free PE fluid from 101 NSCLC patients, 8 mesothelioma and 13 with benign PE was assayed for a panel of 40 cytokines/chemokines using the Luminex system. Comparing NSCLC PE and ...

For the diagnosis of people with pleural effusion, an initial image-assisted Abrams needle biopsy (IA-ANPB) can match medical thoracoscopy (MT) in diagnostic accuracy in some cases, a small randomized ...

Understanding the nature of malignant effusions, teeming with tumor cells and clusters, is critical in comprehending the breadth of cancer's impact. The significant role of tumor clusters, with their ...